Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000029651 | SCV000052303 | uncertain | Congenital adrenal hyperplasia | 2011-08-18 | criteria provided, single submitter | curation | Converted during submission to Uncertain significance. |
Prevention |
RCV003904868 | SCV004724582 | uncertain significance | CYP21A2-related disorder | 2024-02-27 | no assertion criteria provided | clinical testing | The CYP21A2 c.293-7C>G variant is predicted to interfere with splicing. This variant has been reported in the homo- or hemizygous status in an individual with salt wasting (SW) congenital adrenal hyperplasia (CAH) (Rubtsov et al. 2001. PubMed ID: 22497080; Concolino et al. 2017. PubMedID:28521877). This variant is reported in 0.15% of alleles in individuals of Ashkenazi Jewish descent in gnomAD. This variant falls within a highly paralogous region. Allele frequency data should be interpreted with caution. Of note, this change is predicted to possibly alter splicing by splicing prediction programs (Alamut Visual v1.6.1). Minigene expression studies in cultured mammalian cells show this variant abolishes the acceptor site of intron 2 and results in intron retention (Rubtsov et al. 2001. PubMed ID: 22497080; Concolino et al. 2017. PubMedID:28521877). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |